NCT03914911 is a NA clinical trial of Smart Biopsy Device in Breast Cancer, sponsored by Dune Medical Devices.

Who is sponsoring NCT03914911?

NCT03914911 is sponsored by Dune Medical Devices.

What drugs are being tested in NCT03914911?

Interventions in NCT03914911: Smart Biopsy Device.

What condition does NCT03914911 study?

NCT03914911 studies Breast Cancer, Image Guided Biopsy.

Is NCT03914911 still recruiting?

NCT03914911 is currently status unknown. Last updated 31 January 2020.

Last reviewed 2020-01-31 · How we verify

NCT03914911

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

In Vivo Smart Biopsy Device Protocol In Radiology

Status unknown NA Last updated 31 January 2020

What this trial tests

NA trial testing Smart Biopsy Device in Breast Cancer in 41 participants. Status unknown.

Timeline

14 March 2019

Primary endpoint
28 February 2020

31 March 2020

Quick facts

Lead sponsor	Dune Medical Devices
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	41
Start date	14 March 2019
Primary completion	28 February 2020
Estimated completion	31 March 2020
Sites	2 locations across Israel

Drugs / interventions tested

Smart Biopsy Device

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Image Guided Biopsy — all drugs for Image Guided Biopsy →

Sponsor

Dune Medical Devices

Who can join

18 and older, female only, with Breast Cancer or Image Guided Biopsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to demonstrate the feasibility of use of the Smart Biopsy Device in real clinical settings.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03914911 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dune Medical Devices
Last refreshed: 31 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03914911.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing